Asset Details
Do you wish to reserve the book?
Angiotensin II Type 1–Receptor Activating Antibodies in Renal-Allograft Rejection
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Angiotensin II Type 1–Receptor Activating Antibodies in Renal-Allograft Rejection
Do you wish to request the book?
Angiotensin II Type 1–Receptor Activating Antibodies in Renal-Allograft Rejection
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Angiotensin II Type 1–Receptor Activating Antibodies in Renal-Allograft Rejection
2005
Overview
Although some kidney-transplant recipients with severe vascular rejection have antibodies against HLA antigens, others do not. Severe vascular rejection accompanied by accelerated hypertension, and even convulsions, resembles preeclampsia. Activating antibodies targeting the angiotensin II type 1 receptor have been found in preeclampsia, and the authors sought and detected such antibodies in patients with severe vascular rejection. These results suggest that a pathway mediated by a non-HLA, angiotensin II type 1 receptor may be involved in vascular rejection.
The results suggest that a pathway mediated by a non-HLA, angiotensin II type 1 receptor may be involved in vascular rejection.
Many aspects of T-cell–mediated responses in allograft rejection have been elucidated, yet humoral mechanisms are relatively unexplored. Vascular rejection that is refractory to intensified immunosuppression is the most important predictor of early and late graft loss.
1
The association of antidonor humoral reactivity against HLA antigens and vascular rejection has been established.
2
Other targets of the allograft-directed host response remain elusive. However, alloantibodies against the polymorphic non-HLA system were found in serum obtained before transplantation from patients in whom refractory rejection developed after they received kidney transplants from HLA-identical siblings.
3
Allograft endothelium may be a primary target of the cytopathic actions . . .
Publisher
Massachusetts Medical Society
Subject
Angiotensin II Type 1 Receptor Blockers - pharmacology
/ Angiotensin II Type 1 Receptor Blockers - therapeutic use
/ Animals
/ Biological and medical sciences
/ Female
/ Graft Rejection - immunology
/ Humans
/ Immunoglobulins, Intravenous - therapeutic use
/ Kidney Transplantation - immunology
/ Male
/ Mitogen-Activated Protein Kinase 3 - metabolism
/ Patients
/ Rats
/ Receptor, Angiotensin, Type 1 - immunology
/ Transcription Factors - metabolism
